ACE Report Cover
AAHKS 2024: IV Meloxicam versus IV Ketorolac for Pain Control Following TJA
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
PERI-OPERATIVE
AAHKS 2024: IV Meloxicam versus IV Ketorolac for Pain Control Following TJA .

Postoperative Pain and Analgesic Use After Preoperative Methadone for Total Knee Arthroplasty, a Prospective Randomized Double-Blind Study

One hundred thirty-five patients undergoing primary TKA were randomized to receive either a single preoperative dose of methadone (10 mg; n=67) or oxycodone (10 mg; n=68). The primary outcome was postoperative opioid consumption measured in Morphine Milligram Equivalents (MME) over a two-week period. Secondary outcomes included daily MME use from postoperative day (POD) 0 to POD4 and pain scores assessed via Visual Analog Scale (VAS). Outcomes were tracked continuously for two weeks. Overall, the methadone group demonstrated significantly lower daily MME use from POD0 to POD4 (e.g., POD0: 19.5 vs. 26.3; p=0.005), although the total two-week MME difference was not statistically significant (268.6 vs. 310.9; p=0.225). Pain scores were similar between groups, except on POD1 (p=0.027). These findings suggest preoperative methadone reduces early postoperative opioid use, warranting further study on optimal dosing and long-term risks.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAHKS 2024: IV Meloxicam versus IV Ketorolac for Pain Control Following TJA. ACE Report. 2025;307(1):40. Available from: https://myorthoevidence.com/AceReport/Show/aahks-2024-iv-meloxicam-versus-iv-ketorolac-for-pain-control-following-tja

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report